Directions for perinatal pharmacoepidemiology studies in Japan

Taku Obara^{1

2

3}

Affiliations

¹ Department of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
² Division of Molecular Epidemiology, Graduate School of Medicine, Tohoku University, Sendai, Japan.
³ Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan.

Editorial

Taku Obara. Congenit Anom (Kyoto). 2024 Jan.

. 2024 Jan;64(1):4-5.

doi: 10.1111/cga.12549. Epub 2024 Jan 1.

Taku Obara^{1

2

3}

¹ Department of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
² Division of Molecular Epidemiology, Graduate School of Medicine, Tohoku University, Sendai, Japan.
³ Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan.

No abstract available

References

1. Yakuwa N, Murashima A, Miyazaki S. Investigation on the accumulation of background and pregnancy outcome information on cases consulted by the Japan Drug Information Institute in Pregnancy. Congenital Anorm. 2024;64(1):6-16. doi:10.1111/cga.12547
1. Sakai T, Sato Y, Hatakeyama S, et al. Identification and international comparison of drugs contraindicated for pregnant 34 women in the package inserts. Jpn J Drug Inform. 2023; In press.
1. Viguera AC. Accumulation of reproductive safety data for second-generation atypical antipsychotics: a call to accelerate the process. J Clin Psychiatry. 2022;83(4):22com14489.
1. Nagai K, Tanaka T, Kodaira N, Kimura S, Takahashi Y, Nakayama T. Data resource profile: JMDC claims database sourced from health insurance societies. J Gen Fam Med. 2021;22(3):118-127.
1. Takazono T, Tashiro M, Ota Y, et al. Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan. Sci Rep. 2020;10(1):15033.